AtriCure

Summary

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

History

AtriCure was founded in 2000, in Cincinnati, Ohio, by Dr. David Drachman, a cardiac surgeon, and Stephen Johnson, an engineer. AtriCure brought the first intelligent epicardial ablation system to market in 2002 and the first atrial fibrillation (Afib) ablation device in 2004. Today, AtriCure provides innovative ablation systems and meanostomies to clinical partners around the world.

Mission

We improve the lives of our clinicians, their patients, and their families through innovative technologies designed to treat cardiac arrhythmias and reduce the risk of stroke and other related disorders.

Vision

Our vision is to lead the medical technology industry by advancing the field of cardiac arrhythmias with a continuous commitment to innovation, quality, and service.

References

https://in.investing.com/equities/atricure

https://finance.yahoo.com/quote/ATRC/profile?p=ATRC

https://www.crunchbase.com/organization/atricure

https://sec.report/CIK/0001323885

https://companiesmarketcap.com/

https://www.atricure.com

AtriCure

Share

Contacts

Follow Us

AtriCure

Share

Contacts

Follow Us